arrow
J

June-Won Cheong

Yonsei University
H指数:36
被引数:4,611

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction to: Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia

更正:波纳替尼在重度预治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病患者中的真实世界疗效

2026-10-240
OAAI
Long-term efficacy and safety of romiplostim plus immunosuppressive therapy as first-line treatment in patients with aplastic anaemia: 2-year interim analysis of observational study of two clinical trials

罗米司亭联合免疫抑制疗法作为再生障碍性贫血患者的一线治疗的长期疗效和安全性:两项临床试验的观察性研究的2年中期分析

2026-08-210
OAAI
QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD–negative acute myeloid leukemia

QUANTUM-Wild:一项关于Quizartinib在初诊FLT3-ITD阴性急性髓性白血病中的III期随机临床试验

2026-07-110
OAAI
Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia

强预处理慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病患者的波纳替尼真实世界疗效

2026-05-220
OAAI
Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b

中性粒细胞与淋巴细胞比值减半作为接受罗培干扰素alfa-2b治疗的真性红细胞增多症患者分子应答的替代指标

2026-03-300
OA
Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia

串联下一代测序用于检测急性髓系白血病中的胚系易感性

2026-02-012
OAAI
Age- and sex-adjusted genomic differences between Korean and Beat AML cohorts

韩国和Beat AML队列经年龄和性别校正的基因组差异

2026-01-010
OA
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

PET4反应与ECHELON-2试验中CD30+外周T细胞淋巴瘤患者接受BV-CHP vs CHOP治疗的结局相关性研究

2025-08-210
OAAI
Ropeginterferon in Low-Risk Patients with Polycythemia Vera

罗普干扰素在低风险真性红细胞增多症患者中的应用

BLOOD
IF23.1
2024-11-050
PRE
Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

再生障碍性贫血患者接受免疫抑制疗法联合罗米司亭作为一线治疗,在2/3期试验中的长期随访:两年期中期分析

BLOOD
IF23.1
2024-11-050
PRE
PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

PHI-101,一种新型FLT3 TKI,在FLT3突变型复发性/难治性AML中显示出临床疗效

BLOOD
IF23.1
2024-11-050
PRE
Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

串联下一代测序在急性髓系白血病中胚系易感性的检测应用

BLOOD
IF23.1
2024-11-050
PRE
Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

通过将中性粒细胞与淋巴细胞比率(NLR)减半来预测真性红细胞增多症(Polycythemia Vera)使用Ropeginterferon治疗的分子应答

BLOOD
IF23.1
2024-11-050
PRE